Evidence map›Paper›PMID 39745389›Full record

Observational studymBio2025

Are we serologically prepared against an avian influenza pandemic and could seasonal flu vaccines help us?

Iván Sanz-Muñoz, Javier Sánchez-Martínez, Carla Rodríguez-Crespo, Corina S Concha-Santos, Marta Hernández, Silvia Rojo-Rello, Marta Domínguez-Gil, Ahmed Mostafa, Luis Martinez-Sobrido, Jose M Eiros and 1 more

Abstract readObservational Study
In one paragraph

Observational study in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Seasonal Influenza Vaccination in People who Have Contact With Birds.Influenza and other respiratory viruses · 2025
    Article
  15. Harnessing Antiviral Peptides: From Molecular Mechanisms to Clinical Translation.Current research in pharmacology and drug discovery · 2025
    Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Iván Sanz-Muñoz *National Influenza Centre, Hospital Clinico Universitario de Valladolid, Valladolid, Spain.ORCID 0000-0003-4725-6663
Javier Sánchez-MartínezNational Influenza Centre, Hospital Clinico Universitario de Valladolid, Valladolid, Spain.
Carla Rodríguez-CrespoNational Influenza Centre, Hospital Clinico Universitario de Valladolid, Valladolid, Spain.
Corina S Concha-SantosCenter for Animal Health Research, CISA-INIA-CSIC, Madrid, Spain.
Marta HernándezNational Influenza Centre, Hospital Clinico Universitario de Valladolid, Valladolid, Spain.
Silvia Rojo-RelloNational Influenza Centre, Hospital Clinico Universitario de Valladolid, Valladolid, Spain.
Marta Domínguez-GilNational Influenza Centre, Hospital Clinico Universitario de Valladolid, Valladolid, Spain.
Ahmed MostafaTexas Biomedical Research Institute, San Antonio, Texas, USA.
Luis Martinez-SobridoTexas Biomedical Research Institute, San Antonio, Texas, USA.ORCID 0000-0001-7084-0804
Jose M EirosNational Influenza Centre, Hospital Clinico Universitario de Valladolid, Valladolid, Spain.
Aitor Nogales *Center for Animal Health Research, CISA-INIA-CSIC, Madrid, Spain.ORCID 0000-0002-2424-7900

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00018 · NIAID · UNIVERSITY OF GEORGIA · PI TOMPKINS, S. MARK · 2021 to 2025
$21.6M
Oxidant Stress &Apoptosis in Chronic Cigarette ExposureF31NR009598 · NINR · UNIVERSITY OF SOUTH FLORIDA · PI MONTPETIT, ALISON JONES · 2005 to 2007
$87k
EC | HORIZON EUROPE Framework Programme (Horizon Europe) 101046133Junta de Castilla y León (JCYL) GRS2557/A/22MEC | Consejo Superior de Investigaciones Científicas (CSIC) 202240I182NIAID NIH HHS 75N93021C00018NINR NIH HHS F31 NR009598
6 · The paper itself

Abstract

The current situation with H5N1 highly pathogenic avian influenza virus (HPAI) is causing a worldwide concern due to multiple outbreaks in wild birds, poultry, and mammals. Moreover, multiple zoonotic infections in humans have been reported. Importantly, HPAI H5N1 viruses with genetic markers of adaptation to mammals have been detected. Together with HPAI H5N1, avian influenza viruses H7N9 (high and low pathogenic) stand out due to their high mortality rates in humans. This raises the question of how prepared we are serologically and whether seasonal vaccines are capable of inducing protective immunity against these influenza subtypes. An observational study was conducted in which sera from people born between years 1925-1967, 1968-1977, and 1978-1997 were collected before or after 28 days or 6 months post-vaccination with an inactivated seasonal influenza vaccine. Then, hemagglutination inhibition, viral neutralization, and immunoassays were performed to assess the basal protective immunity of the population as well as the ability of seasonal influenza vaccines to induce protective responses. Our results indicate that subtype-specific serological protection against H5N1 and H7N9 in the representative Spanish population evaluated was limited or nonexistent. However, seasonal vaccination was able to increase the antibody titers to protective levels in a moderate percentage of people, probably due to cross-reactive responses. These findings demonstrate the importance of vaccination and suggest that seasonal influenza vaccines could be used as a first line of defense against an eventual pandemic caused by avian influenza viruses, to be followed immediately by the use of more specific pandemic vaccines.IMPORTANCEInfluenza A viruses (IAV) can infect and replicate in multiple mammalian and avian species. Avian influenza virus (AIV) is a highly contagious viral disease that occurs primarily in poultry and wild water birds. Due to the lack of population immunity in humans and ongoing evolution of AIV, there is a continuing risk that new IAV could emerge and rapidly spread worldwide, causing a pandemic, if the ability to transmit efficiently among humans was gained. The aim of this study is to analyze the basal protection and presence of antibodies against IAV H5N1 and H7N9 subtypes in the population from different ages. Moreover, we have evaluated the humoral response after immunization with a seasonal influenza vaccine. This study is strategically important to evaluate the level of population immunity that is a major factor when assessing the impact that an emerging IAV strain would have, and the role of seasonal vaccines to mitigate the effects of a pandemic.

Indexed as

Antibodies, ViralInfluenza A Virus, H5N1 SubtypeInfluenza A Virus, H7N9 SubtypeInfluenza, HumanInfluenza VaccinesPandemicsAdultAnimalsFemaleHemagglutination Inhibition TestsHumansInfluenza in BirdsMaleMiddle AgedSeasonsSpainAntibodies, ViralInfluenza Vaccinesavian influenzainfluenza A virusinfluenza vaccinenanoluciferaseneutralizing antibodiespandemicseroconversionseroprotection

Identifiers

PMID39745389
PMCPMC11796349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.